Adial Pharmaceuticals, Inc.ADILNASDAQ
Loading
SG&A Expense Growth Recovery in ProgressRecovering
Percentile Rank60
5Y CAGR-33.2%
Year-over-Year Change
Year-over-year SG&A expense growth
5Y CAGR
-33.2%/yr
Long-term compound
Percentile
P60
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
2 yr
Consecutive growthRecovering
| Period | Value |
|---|---|
| 2025 | 2.46% |
| 2024 | -10.06% |
| 2023 | -36.91% |
| 2022 | -4.66% |
| 2021 | 84.14% |
| 2020 | 18.59% |
| 2019 | -35.35% |
| 2018 | 713.94% |
| 2017 | 207.25% |
| 2016 | -46.76% |